Her2/neu Expression by Reverse Transcriptase-Polymerase Chain Reaction in the Peripheral Blood of Prostate Cancer Patients

Grasso Y.Z. , Gupta M.K. , Levin H.S. , Zippe C.D. , Klein E.A. : Combined nested RT-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in prostate cancer patients: correlation with pathological stage. Cancer Res, 58: 1456–1459, 1998.

Schmidt B. , Anastasiadis A.G. , Seifert H.H. , Franke K.H. , Oya M. , Ackermann R. : Detection of circulating prostate cells during radical prostatectomy by standardized PSMA RT-PCR: association with positive lymph nodes and high malignant grade. Anticancer Res, 23: 3991–3999, 2003.

Seiden M.V. , Kantoff P.W. , Krithivas K. , Propert K. , Bryant M. , Haltom E. , Gaynes L. , Kaplan I. , Bubley G. , DeWolf W. : Detection of circulating tumor cells in men with localized prostate cancer. J Clin Oncol, 12: 2634–2639, 1994.

Tobias-Machado M. , Fonseca F. , Fantinato A.P. , Bendit I. , Wroclawski M.L. , Wroclawski E. , del Giglio A. : Cytokeratin 19 expression by reverse transcriptase-polymerase chain reaction in the peripheral blood of prostate cancer patients. Tumori, 91: 248–252, 2005.

Shariat S.F. , Kattan M.W. , Song W. , Bernard D. , Gottenger E. , Wheeler T.M. , Slawin K.M. : Early postoperative peripheral blood reverse transcription PCR assay for prostate-specific antigen is associated with prostate cancer progression in patients undergoing radical prostatectomy. Cancer Res, 63: 5874–5878, 2003.

Shariat S.F. , Gottenger E. , Nguyen C. , Song W. , Kattan M.W. , Andenoro J. , Wheeler T.M. , Spencer D.M. , Slawin K.M. : Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy. Cancer Res, 62: 5974–5979, 2002.

Bianco F.J. Jr. , Powell I.J. , Cher M.L. , Wood D.P. Jr. : Presence of circulating prostate cancer cells in African American males adversely affects survival. Urol Oncol, 7: 147–152, 2002.

Kantoff P.W. , Halabi S. , Farmer D.A. , Hayes D.F. , Vogelzang N.A. , Small E.J. : Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer. J Clin Oncol, 19: 3025–3028, 2001.

Mejean A. , Vona G. , Nalpas B. , Damotte D. , Brousse N. , Chretien Y. , Dufour B. , Lacour B. , Brechot C. , Paterlini-Brechot P. : Detection of circulating prostate-derived cells in patients with prostate adenocarcinoma is an independent risk factor for tumor recurrence. J Urol, 163: 2022–2029, 2000.

Thiounn N. , Saporta F. , Flam T.A. , Pages F. , Zerbib M. , Vieillefond A. , Martin E. , Debre B. , Chevillard S. : Positive prostate-specific antigen circulating cells detected by reverse transcriptase-polymerase chain reaction does not imply the presence of prostatic micrometastases. Urology, 50: 245–250, 1997.

Yarden Y. : Biology of HER2 and its importance in breast cancer: Oncology, 61 (Suppl 2): 1–13, 2001.

Piccart-Gebhart M.J. , Procter M. , Leyland-Jones B. , Goldhirsch A. , Untch M. , Smith I. , Gianni L. , Baselga J. , Bell R. , Jackisch C. , Cameron D. , Dowsett M. , Barrios C.H. , Steger G. , Huang C.S. , Andersson M. , Inbar M. , Lichinitser M. , Láng I. , Nitz U. , Iwata H. , Thomssen C. , Lohrisch C. , Suter T.M. , Rüschoff J. , Suto T. , Greatorex V. , Ward C. , Straehle C. , Mc-Fadden E. , Dolci M.S. , Gelber R.D. : Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med, 353: 1659–1672, 2005.

Slamon D.J. , Leyland-Jones B. , Shak S. , Fuchs H. , Paton V. , Bajamonde A. , Fleming T. , Eiermann W. , Wolter J. , Pegram M. , Baselga J. , Norton L. : Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over-expresses HER2. N Engl J Med, 344: 783–792, 2001.

Ross J.S. , Sheehan C. , Hayner-Buchan A.M. , Ambros R.A. , Kallakury B.V. , Kaufman R. , Fisher H.A. , Muraca P.J. : HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization. Hum Pathol, 28: 827–833, 1997.

Shi Y. , Brands F.H. , Chatterjee S. , Feng A.C. , Groshen S. , Schewe J. , Lieskovsky G. , Cote R.J. : Her-2/neu expression in prostate cancer: high level of expression associated with exposure to hormone therapy and androgen independent disease. J Urol, 166: 1514–1519, 2001.

Gregory C.W. , Whang Y.E. , McCall W. , Fei X. , Liu Y. , Ponguta L.A. , French F.S. , Wilson E.M. , Earp HS III : Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth. Clin Cancer Res, 11: 1704–1712, 2005.

Mellinghoff I.K. , Vivanco I. , Kwon A. , Tran C. , Wongvipat J. , Sawyers C.L. : HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell, 6: 517–527, 2004.

Novaes M. , Bendit I. , Garicochea B. , del Giglio A. : Reverse transcriptase-polymerase chain reaction analysis of cytokeratin 19 expression in the peripheral blood mononuclear cells of normal female blood donors. Mol Pathol, 50: 209–211, 1997.

Fonseca F.L. , Soares H.P. , Manhani A.R. , Bendit I. , Novaes M. , Zatta S.M. , Arias V. , Pinhal M.A. , Weinschenker P. , del Giglio A. : Peripheral blood c-erbB-2 expression by reverse transcriptase-polymerase chain reaction in breast cancer patients receiving chemotherapy. Clin Breast Cancer, 3: 201–205, 2002.

Lin Y.C. , Chen S.C. , Hsueh S. , Lo Y.F. , Chow-Wu Y.H. , Liaw I.C. , Cheng A.J. : Lack of correlation between expression of human mammaglobin mRNA in peripheral blood and known prognostic factors for breast cancer patients. Cancer Sci, 94: 99–102, 2003.

Martinez-Pineiro L. , Rios E. , Martinez-Gomariz M. , Pastor T. , de C.M. , Picazo M.L. , Palacios J. , Perona R. : Molecular staging of prostatic cancer with RT-PCR assay for prostate-specific antigen in peripheral blood and lymph nodes: comparison with standard histological staging and immunohistochemical assessment of occult regional lymph node metastases. Eur Urol, 43: 342–350, 2003.

Krismann M. , Todt B. , Schroder J. , Gareis D. , Muller K.M. , Seeber S. , Schutte J. : Low specificity of cytokeratin 19 reverse transcriptase-polymerase chain reaction analyses for detection of hematogenous lung cancer dissemination. J Clin Oncol, 13: 2769–2775, 1995.

Lintula S. , Stenman U.H. : The expression of prostate-specific membrane antigen in peripheral blood leukocytes. J Urol, 157: 1969–1972, 1997.

Ady N. , Morat L. , Fizazi K. , Soria J.C. , Mathieu M.C. , Prapotnich D. , Sabatier L. , Chauveinc L. : Detection of HER-2/neu-positive circulating epithelial cells in prostate cancer patients. Br J Cancer, 90: 443–448, 2004.

Scher H.I. : HER2 in prostate cancer - a viable target or innocent bystander? J Natl Cancer Inst, 92: 1866–1868, 2000.

Signoretti S. , Montironi R. , Manola J. , Altimari A. , Tam C. , Bubley G. , Balk S. , Thomas G. , Kaplan I. , Hlatky L. , Hahnfeldt P. , Kantoff P. , Loda M. : Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst, 92: 1918–1925, 2000.

Ziada A. , Barqawi A. , Glode L.M. , Varella-Garcia M. , Crighton F. , Majeski S. , Rosenblum M. , Kane M. , Chen L. , Crawford E.D. : The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate, 60: 332–337, 2004.

Bozionellou V. , Mavroudis D. , Perraki M. , Papadopoulos S. , Apostolaki S. , Stathopoulos E. , Stathopoulou A. , Lianidou E. , Georgoulias V. : Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer. Clin Cancer Res, 10: 8185–8194, 2004.

Spector N.L. , Xia W. , Burris H. III , Hurwitz H. , Dees E.C. , Dowlati A. , O'Neil B. , Overmoyer B. , Marcom P.K. , Blackwell K.L. , Smith D.A. , Koch K.M. , Stead A. , Mangum S. , Ellis M.J. , Liu L. , Man A.K. , Bremer T.M. , Harris J. , Bacus S. : Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol, 23: 2502–2512, 2005.